Combinations but Not a Single PlpE Epitope Induces Host Protective Immunity against Pasteurella multocida.
Pasteurella multocida
PlpE
epitope
immunoprotection
synergism
Journal
Infection and immunity
ISSN: 1098-5522
Titre abrégé: Infect Immun
Pays: United States
ID NLM: 0246127
Informations de publication
Date de publication:
15 03 2023
15 03 2023
Historique:
pubmed:
24
2
2023
medline:
21
3
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
Pasteurella multocida is the causative agent of a wide range of diseases (pasteurellosis) and a zoonotic pathogen in humans. Recombinant subunit vaccines are hot spots in recent pasteurellosis vaccine development. A chimeric vaccine is also constructed for rabbit hemorrhagic disease virus (RHDV) protective antigen VP60 chimeric with fragments of Pasteurella multocida protective antigen PlpE. The protective efficacy of the chimeric vaccine against P. multocida is not as high as that of PlpE, and the reason is not well known. In this study, we analyzed the linear B-cell epitopes of PlpE and then assessed the protective efficacy of these epitopes and their combinations. It was found that the immunodominant region of PlpE was mainly located in the region between the 21st to the 185th amino acids from the N terminus. Overlapping peptide scanning results demonstrated that this region contained six nonoverlapping epitopes, and epitope E was the predominant epitope. Chimeric protein antigens were constructed of single nonoverlapping PlpE epitopes or their combinations chimeric with the RHDV VP60 P domain. Immunization with recombinant antigen chimeric with a single PlpE epitope exhibited poor immunoprotection, whereas immunization with recombinant antigen chimeric with PlpE epitope combinations (epitopes A and E; epitopes C and E; epitopes A, C, and E; and epitopes B, D, and F) exhibited significant immunoprotection. In a word, P. multocida protective antigen PlpE contained six nonoverlapping linear B-cell epitopes, and combinations but not a single epitope induced host protective immunity. Our work will give help for future chimeric vaccine design.
Identifiants
pubmed: 36815793
doi: 10.1128/iai.00272-22
pmc: PMC10016081
doi:
Substances chimiques
Epitopes, B-Lymphocyte
0
Recombinant Proteins
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0027222Références
PLoS One. 2012;7(3):e33045
pubmed: 22427942
Curr Top Microbiol Immunol. 2012;361:1-22
pubmed: 22643916
Infect Immun. 2004 Dec;72(12):7265-74
pubmed: 15557652
Front Microbiol. 2018 Feb 06;9:125
pubmed: 29467739
J Virol. 2011 Jan;85(2):753-64
pubmed: 21068235
Vet Microbiol. 2020 May;244:108649
pubmed: 32402342
Vaccine. 2018 Dec 18;36(52):8079-8083
pubmed: 30446176
Expert Rev Vaccines. 2015;14(12):1623-32
pubmed: 26420467
Clin Microbiol Rev. 2013 Jul;26(3):631-55
pubmed: 23824375
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374
Vaccine. 2014 Feb 12;32(8):909-17
pubmed: 24295805
PLoS One. 2012;7(7):e39973
pubmed: 22792202
Acta Microbiol Immunol Hung. 2012 Dec;59(4):485-98
pubmed: 23195557
Sci Rep. 2016 Aug 23;6:31844
pubmed: 27549017
Front Vet Sci. 2020 Apr 15;7:174
pubmed: 32351978
Dev Comp Immunol. 2017 Jun;71:1-7
pubmed: 28119019
Adv Exp Med Biol. 2017;1053:119-153
pubmed: 29549638
J Virol. 2019 Aug 13;93(17):
pubmed: 31189716
Int Microbiol. 2008 Mar;11(1):17-24
pubmed: 18683628
Vet Microbiol. 2010 Jul 29;144(1-2):1-17
pubmed: 20197220
J Virol. 2020 May 4;94(10):
pubmed: 32161178
Lancet Infect Dis. 2015 Feb;15(2):235-40
pubmed: 25467649
Vet Parasitol. 2007 Jun 20;147(1-2):77-88
pubmed: 17481823
Nat Commun. 2021 Feb 17;12(1):1102
pubmed: 33597521
Microb Pathog. 2019 Apr;129:74-77
pubmed: 30710674
Nat Commun. 2020 Aug 7;11(1):3971
pubmed: 32769993
Vaccine. 2007 May 22;25(21):4140-8
pubmed: 17449151
Curr Issues Mol Biol. 2019;32:645-700
pubmed: 31166182
Infect Immun. 1998 Dec;66(12):5613-9
pubmed: 9826333
Trends Immunol. 2018 Jul;39(7):549-561
pubmed: 29789196
Antibodies (Basel). 2018 Jan 04;7(1):
pubmed: 31544858